Theravance Biopharma, Inc. (TBPH) — Stock Price, Chart & Analysis
Theravance Biopharma, Inc. (TBPH) is a Healthcare stock currently trading at $100, up 0.00% on the day. It carries a market capitalization of $884.18M and a trailing P/E ratio of 16.38. Over the past 52 weeks, TBPH has traded between $13.08 and $21.03. Theravance Biopharma, Inc. does not currently pay a regular dividend. View the live TBPH chart, technical opinion, analyst ratings, fundamentals and latest news below.
Theravance Biopharma, Inc. (TBPH) key data
| Price | $100 |
| Change (today) | +0.00% |
| Previous close | $100 |
| Market cap | $884.18M |
| P/E ratio (TTM) | 16.38 |
| EPS (TTM) | $1.04 |
| 52-week high | $21.03 |
| 52-week low | $13.08 |
| Beta | 0.24 |
| Avg. volume | 633.4K |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently asked questions about Theravance Biopharma, Inc. (TBPH)
How much does one share of Theravance Biopharma, Inc. cost?
As of the latest update, one share of Theravance Biopharma, Inc. (TBPH) trades at $100 (+0.00% today).
What is Theravance Biopharma, Inc.'s market cap?
Theravance Biopharma, Inc. has a market capitalization of approximately $884.18M.
What is Theravance Biopharma, Inc.'s P/E ratio?
Theravance Biopharma, Inc. has a trailing price-to-earnings (P/E) ratio of 16.38.
What is Theravance Biopharma, Inc.'s earnings per share (EPS)?
Theravance Biopharma, Inc.'s trailing twelve-month EPS is $1.04.
Does Theravance Biopharma, Inc. pay a dividend?
Theravance Biopharma, Inc. does not currently pay a regular dividend.
What is Theravance Biopharma, Inc.'s 52-week trading range?
Over the past year, TBPH has traded between $13.08 and $21.03.
What is the analyst price target for Theravance Biopharma, Inc.?
The mean analyst price target for Theravance Biopharma, Inc. is $17.67. This is informational only and not investment advice.
Latest Theravance Biopharma, Inc. (TBPH) news
- Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue?News · Sep 9, 2026
- Zymeworks agrees to buy Theravance Biopharma for $929mNews · Jun 30, 2026
- Sector Update: Healthcare Stocks Higher Late AfternoonNews · Jun 29, 2026
- Zymeworks To Buy Theravance Biopharma In $929M Deal – A Look At What This Deal Means For TBPH ShareholdersNews · Jun 29, 2026
- Zymeworks to Acquire Theravance Biopharma in $929 Million DealNews · Jun 29, 2026
- THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHTNews · Jun 29, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live TBPH dashboard…